Failure of the azithromycin and ethambutol combination regimen in the hollow-fibre system model of pulmonary Mycobacterium avium infection is due to acquired resistance

Meta-analyses and the evidence base for microbial outcomes in the treatment of pulmonary Mycobacterium avium–intracellulare complex disease

(2017) Jotam G. Pasipanodya et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

A novel ceftazidime/avibactam, rifabutin, tedizolid and moxifloxacin (CARTM) regimen for pulmonary Mycobacterium avium disease

(2017) Devyani Deshpande et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Azithromycin Dose To Maximize Efficacy and Suppress Acquired Drug Resistance in Pulmonary Mycobacterium avium Disease

(2016) Devyani Deshpande et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Thioridazine as Chemotherapy for Mycobacterium avium Complex Diseases

(2016) Devyani Deshpande et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The Antibiotic Resistance Arrow of Time: Efflux Pump Induction Is a General First Step in the Evolution of Mycobacterial Drug Resistance

(2012) Aurelia M. Schmalstieg et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Nontuberculous Mycobacterial Lung Disease Prevalence at Four Integrated Health Care Delivery Systems

(2010) D. Rebecca Prevots et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Moxifloxacin Pharmacokinetics/Pharmacodynamics and Optimal Dose and Susceptibility Breakpoint Identification for Treatment of Disseminated Mycobacterium avium Infection

(2010) D. Deshpande et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Ethambutol Optimal Clinical Dose and Susceptibility Breakpoint Identification by Use of a Novel Pharmacokinetic-Pharmacodynamic Model of Disseminated Intracellular Mycobacterium avium

(2010) D. Deshpande et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Non-tuberculous mycobacteria in HIV-negative patients with pulmonary disease in Lisbon, Portugal

(2010) António Amorim et al.   SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES